Home / Business and Economy / Biotech IPO Rush: Odyssey & Mobia Seek Public Markets
Biotech IPO Rush: Odyssey & Mobia Seek Public Markets
18 Apr
Summary
- Odyssey Therapeutics and Mobia Medical filed for IPOs amid strong biotech investor demand.
- Odyssey's lead drug targets ulcerative colitis and Crohn's disease.
- Mobia Medical's Vivistim System is approved for stroke survivors.
Biotech companies Odyssey Therapeutics and Mobia Medical have initiated filings for their initial public offerings, signaling a strong investor appetite for the sector. Odyssey Therapeutics, focusing on autoimmune and inflammatory diseases, has advanced a drug candidate for ulcerative colitis and Crohn's disease.
Mobia Medical, which develops medical devices for stroke survivors, is also seeking to go public. Its Vivistim System has received FDA approval for individuals recovering from chronic ischemic strokes.
These filings occur as the Nasdaq Biotechnology Index has seen a significant rise, reflecting heightened investor confidence. Healthcare peers have also experienced notable successes, with recent IPOs from other companies showing strong market performance.
